Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

MedlinePlus Drug Information: Alosetron Alosetron may cause serious gastrointestinal (GI; affecting the stomach or intestines) side effects including ischemic colitis (decreased blood flow to the bowels) and severe constipation that may need to be treated in a hospital and may rarely cause death. Alosetron is used to treat diarrhea, pain, cramps, and the feeling of an urgent need to have bowel movements caused by irritable bowel syndrome (IBS; a condition that causes stomach pain, bloating, constipation, and diarrhea) in women who have diarrhea as their main symptom and have not been helped by other treatments. Alosetron is in a class of medications called serotonin antagonists. www.nlm.nih.gov /medlineplus/druginfo/medmaster/a601230.html   (1120 words)

Alosetron Alosetron inhibits N-acetyltransferase which may influence the metabolism of drugs such as isoniazid, procainamide, and hydralazine but there has not been any investigation of this. Alosetron is a potent and selective antagonist of a subtype of the serotonin receptor, 5-HT receptor. Alosetron is metabolized by CYP2C9, 3A4, and 1A2. www.musc.edu /pharmacyservices/Drugs/A/Alosetron.htm   (1005 words)

Alosetron - Wikipedia, the free encyclopedia Alosetron, while being a 5-HT antagonist like ondansetron, is not an antiemetic. Alosetron has an antagonist action on the 5-HT receptors of the enteric nervous system of the gastrointestinal tract. Alosetron was withdrawn in 2000 following the association of alosetron with serious life-threatening gastrointestinal adverse effects. en.wikipedia.org /wiki/Alosetron   (161 words)

Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro -- Bush et al. ... Alosetron (Lotronex) is a serotonin subtype 3 (5-HT) receptor antagonist that alleviates symptoms of irritable bowel syndrome Although effects of alosetron were indistinguishable in colonic preparations from both genders, the threshold for effects of alosetron was lower in small intestine preparation from female mice compared with males. alosetron on rat 5-HT receptors was 9.8 (13), whereas in the ajpgi.physiology.org /cgi/content/full/281/4/G974   (4012 words)

DrugsWatcher.com Articles on Drug names > ALOSETRON HYDROCHLORIDE   (Site not responding. Last check: 2007-11-07) Alosetron, approved by the Food and Drug Administration in February 2000, had been used to treat the diarrhoea predominant form of irritable bowel syndrome. Alosetron is used to treat severe irritable bowel syndrome (IBS) in women whose main symptom is diarrhea and who failed to respond to previous treatment... In each study, alosetron was significantly more effective than placebo in providing relief from IBS pain and discomfort and in reducing the percentage of days with urgency. www.drugswatcher.com /ALOSETRON_HYDROCHLORIDE_s173.html   (910 words)

alosetron (oral) - [Medication] Alosetron should be prescribed only by a qualified doctor who is enrolled in a prescribing program specific for this drug. Alosetron is used to treat severe, chronic irritable bowel syndrome (IBS) in women who have had diarrhea as the main symptom for at least 6 months. Alosetron is not a cure for irritable bowel syndrome. www.peacehealth.org /kbase/multum/d04516a1.htm   (1432 words)

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial The 5-HT receptor antagonist alosetron has been assessed in patients with IBS, and dose-ranging studies showed that, in women, 1 mg alosetron twice daily was the most effective dose for improving IBS abdominal pain and discomfort, urgency, stool frequency, and stool consistency. One patient in the alosetron group and two in the placebo group withdrew from the study before receiving the first dose and were not included in the safety analysis. Alosetron significantly decreased urgency, stool frequency, and stool consistency, compared with placebo (where a decrease in stool consistency corresponds to an increase in stool firmness; figure 4). www.pediatria.unina.it /JAMA/The_Lancet/article1035.htm   (3280 words)

alosetron - Digestion and Digestive-Related Information on MedicineNet.com Alosetron (Lotronex) was approved for marketing by the FDA in February, 2000, but was withdrawn from the market in November, 2000, because of serious, life-threatening, gastrointestinal side effects. DRUG INTERACTIONS: While alosetron is being broken down and eliminated by the liver, it may affect several enzymes in the liver that are responsible for the elimination of other drugs, and, therefore, it may increase or decrease the blood levels of these other drugs. Other drugs also may alter the way alosetron is eliminated by the liver and increase or decrease blood levels of alosetron, but the effects of these drugs on alosetron have not been tested. www.medicinenet.com /alosetron/article.htm   (872 words)

Inward Currents in Neurons from Newborn Guinea Pig Intestine: Mediation by 5-Hydroxytryptamine Type 3 Receptors -- Zhai ... The effect of alosetron on the peak amplitude of the response to 5-HT was independent of membrane potential. A, increasing concentrations of alosetron reversibly inhibit the response to 5-HT (40 µM); the magnitude of alosetron inhibition is greater at higher concentrations. The percent inhibition of the response to 5-HT is plotted as a function of the log of the alosetron concentration. jpet.aspetjournals.org /cgi/content/full/291/1/374   (6300 words)

New This Month — The Family Health Guide In a study of how the drug alosetron affects patients suffering from diarrhea-predominant IBS, results showed that alosetron significantly improved multiple symptoms of the disorder, but these improvements were gained in exchange for an increased rate of constipation. While alosetron was effective at relieving diarrhea, 30% of the women taking the drug reported experiencing constipation compared with only 3% of the women taking the placebo. Alosetron has been approved by the FDA but exactly how best to utilize it in the treatment of IBS will be better understood over time. www.health.harvard.edu /fhg/NTMarchive/600.shtml   (3778 words)

PersonalMD.com Health Encyclopedia However, more study is needed to compare alosetron with other existing drugs and to determine if it is cost effective, according Dr. Tony Lembo from Harvard Medical School in Boston, Massachusetts, who wrote a commentary accompanying the report in the March 25th issue of The Lancet. Overall, 41% of the women taking alosetron reported satisfactory relief of pain and discomfort compared with 29% of women taking a placebo, the authors report. According to Mangel, the drug company is "currently testing alosetron in larger studies of males and adolescents with IBS, as well as in patients with alternating IBS. www.personalmd.com /encnews.jsp?f=n0327064222.html   (451 words)

Davis's Drug Guide for Nurses, Eighth Edition Counsel patients about the risks and benefits of alosetron and the impact of IBS symptoms on their life. Alosetron should be resumed only after constipation has resolved and on the advice of their health care professional. Treatment with alosetron should not be resumed in patients who develop ischemic colitis. www.drugguide.com /monograph_library/new_releases/alosetron.htm   (394 words)

Irritable Bowel Syndrome   (Site not responding. Last check: 2007-11-07) Alosetron is used to treat severe, chronic, irritable bowel syndrome (IBS) in women who have diarrhea as the main symptom (diarrhea-predominant) and who have not responded to other treatments. Alosetron has not been shown to be helpful for men with irritable bowel syndrome. In rare cases, alosetron has caused ischemic colitis, which is caused by reduced blood flow to certain parts of the intestines. ucsu.colorado.edu /~cowger/hypertext/alosetron.html   (297 words)

Alosetron - Drugs & Vitamins - Drug Library - DrugDigest ALOSETRON (Lotronex®) is used to treat irritable bowel syndrome (IBS) in women who have severe diarrhea as the primary symptom and who have not had success with other IBS treatments. Alosetron helps to reduce the cramping, abdominal pain, discomfort, urgency (sudden need to move the bowels), and diarrhea caused by IBS. Alosetron is available only from health care providers who participate in a special Prescribing Program because this drug may cause serious side effects. www.drugdigest.org /DD/DVH/Uses/0,3915,5015|Alosetron,00.html   (878 words)

Alosetron (Systemic) Alosetron (a-LOE-se-tron) is a medicine used to treat irritable bowel syndrome (IBS) in women who have diarrhea as their main symptom. Alosetron does not cure IBS and it may not help every person who takes it. Stop taking alosetron and check with your doctor right away if you become constipated or have symptoms of poor blood flow to your intestines (ischemic colitis), such as new or worsening abdominal pain, bloody diarrhea, or blood in the stool. allnutritionals.com /drugs/a/alosetron-systemic.shtml   (1094 words)

First Bowel-Specific Serotonin Receptor for IBS - Brief Article American Family Physician - Find Articles The patients randomized to alosetron therapy were similar to those given placebo in all important demographic and symptomatic variables. Relief of pain and discomfort was reported by 133 (41 percent) of the patients treated with alosetron and 94 (29 percent) of the patients receiving placebo. Constipation was reported by 30 percent of alosetron patients compared with 3 percent of those receiving placebo, and 33 patients in the alosetron group withdrew from the study because of this symptom. www.findarticles.com /p/articles/mi_m3225/is_5_62/ai_65174238   (647 words)

Public Citizen | Publications - Testimony Before FDA Advisory Committee Concerning Alosetron (LOTRONEX) (HRG ... The dose of alosetron used in this Lancet study  (2 mg/day) is twice as much as the company is proposing (1 mg per day) in its new marketing plan being discussed at this meeting. According to the FDA Medical Officer review of the use of this lower dose in dose-ranging studies prior to approval, there is no adequate evidence from placebo-controlled trials that the 1-mg per day dose is significantly better than a placebo. We do not think that the necessary combination of safeguards to reduce the risk from alosetron can be accomplished under conditions of marketing; it needs to be done under a restricted IND. One of the ways being considered is the so-called Subpart H section of FDA regulations. www.citizen.org /publications/release.cfm?ID=7170   (1543 words)

Alosetron for irritable bowel syndrome Alosetron is used to treat severe irritable bowel syndrome (IBS) in some women who have failed to respond to other treatments for severe diarrhea. After alosetron was first approved by the U.S. Food and Drug Administration (FDA) for treatment of IBS, some people taking the medication suffered from serious side effects, including severe constipation or reduced blood flow to the large intestine (ischemic colitis). Alosetron is for use only in women who suffer from severe IBS whose main symptom is diarrhea and who failed to respond to previous treatment. www.webmd.com /ibs/alosetron-for-irritable-bowel-syndrome   (491 words)

Public Citizen | Publications - Testimony before FDA advisory committee concerning alosetron (Lotronex) (HRG ... Since drug safety must always be viewed in the context of drug benefit, a review of the evidence of benefit for alosetron in the treatment of diarrhea-predominant irritable bowel syndrome is appropriate. Assuming the accuracy of the GSK estimate of 9,365 patients getting alosetron during the RMP, the rate of ischemic colitis reports (8/10,000 patients or 0.85 per 1000) is actually higher than the rate of spontaneous reports during the earlier 2000 marketing,   before market withdrawal (85/275000 patients or 0.31 per 1000). But alosetron joins an increasing number of other drugs, none with unique, clinically significant benefits, that have been the subject of ultimately failed FDA-approved risk management programs (the diabetes drug Rezulin, the pain-killer Duract, the gastrointestinal drug Cisapride, the blood pressure drug Posicor) and were taken off the market. www.citizen.org /publications/release.cfm?ID=7314   (1211 words)

Lotronex (Alosetron Hydrochloride) drug description - prescription drugs and medications at RxList The active ingredient in LOTRONEX Tablets is alosetron hydrochloride (HCl), a potent and selective antagonist of the serotonin 5-HT Alosetron is achiral and has the empirical formula: C Alosetron is a white to beige solid that has a solubility of 61 mg/mL in water, 42 mg/mL in 0.1M hydrochloric acid, 0.3 mg/mL in pH 6 phosphate buffer, and www.rxlist.com /cgi/generic/alosetron.htm   (409 words)

Drug for irritable bowel syndrome taken off the market -- Charatan 321 (7274): 1429 -- BMJ Alosetron hydrochloride (Lotronex), a prescription drug manufactured by GlaxoWellcome, and used to treat irritable bowel syndrome Alosetron, approved by the Food and Drug Administration in February 2000, had been used to treat the diarrhoea predominant Alosetron is contraindicated in women with a history of intestinal obstruction, stricture, toxic megacolon, gastrointestinal bmj.bmjjournals.com /cgi/content/full/321/7274/1429/a   (378 words)

DG DISPATCH - ACG: Alosetron Reduces Lost Work Time in Women with Irritable Bowel Syndrome   (Site not responding. Last check: 2007-11-07) NEW YORK, N.Y. -- October 16, 2000 -- The 5-HT3 receptor antagonist, alosetron, decreases time lost from work in women with irritable bowel syndrome whose predominant symptom is diarrhea, new results suggest. The data were presented at the 65th Annual Scientific Meeting of the American College of Gastroenterology, in New York, and are based on the results of two trials in 903 women 18 years of age and older with diarrhea-predominant irritable bowel syndrome (IBS) and a normal gastrointestinal anatomy. Sixty-five percent of alosetron patients compared with 49 percent of placebo patients missed no days at week 12. www.pslgroup.com /dg/1E48E6.htm   (350 words)

Alosetron: a case study in regulatory capture, or a victory for patients' rights? Alosetron: a case study in regulatory capture, or a victory for patients' rights? GlaxoSmithKline's alosetron has been approved, withdrawn, and now approved again (box 1), and outside critics allege it is Alosetron is one of eight drugs approved in the United States in the past decade and subsequently withdrawn for safety reasons, www.vaccinationnews.com /DailyNews/September2002/Alosetron13.htm   (2867 words)

Alosetron Drug Information Children-Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of alosetron in children with use in other age groups. Older adults-Older adults or adults weak from an illness may be especially sensitive to the effects of alosetron. Dosing-The dose of alosetron may be different for different patients. www.drugs.com /cons/Alosetron.html   (1585 words)

Nursing Spectrum Drug Handbook   (Site not responding. Last check: 2007-11-07) Alosetron inhibits activation of these cation channels, leading to modulation of the enteric nervous system. Warnings: Alosetron has been associated with serious GI adverse reactions (including ischemic colitis and serious complications of constipation), resulting in hospitalization, blood transfusion, surgery, and death. Its use is indicated only for women with severe, diarrhea-predominant IBS who have chronic IBS symptoms (6 months or longer) unresponsive to conventional therapy, and have no anatomic or biochemical GI abnormalities. www.nursesdrughandbook.com /drug_approvals/Alosetronhydrochloride.cfm   (460 words)

Healthopedia.com Drugs Information - Alosetron : Before Using (Lotronex) Breast-feeding—It is not known whether alosetron passes into human breast milk. Children—Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of alosetron in children with use in other age groups. Older adults—Older adults or adults weak from an illness may be especially sensitive to the effects of alosetron. www.healthopedia.com /drugs/detailed/alosetron/before-using.html   (410 words)

GlaxoSmithKline Clinical Trial Register - alosetron studies An open-label, non-randomized, two-way cross-over trial to evaluate the effect of multiple-dose alosetron administration (1 mg PO BID for 14 days) on the pharmacokinetics of single-dose fluoxetine (PROZAC) administration in healthy subjects. An open-label, non-randomized, cross-over trial to evaluate the effect of alosetron (1 mg PO BID for 5 days) on the pharmacokinetics of single-dose amitriptyline (Elavil) administration in healthy subjects. A study to investigate the effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome (IBS). ctr.gsk.co.uk /Summary/alosetron/studylist.asp   (1569 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.